Surrozen (SRZN) vs YD Bio (YDES)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Surrozen (SRZN) has outperformed YD Bio (YDES) over the past year, gaining 72.6% versus a loss of 70.5%. YD Bio is the larger company by market cap ($419.3 million vs $275.5 million), about 1.5 times the size. YD Bio converts more of its revenue into profit, with a net margin of -1392.6% versus -6960.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SRZN | YDES |
|---|---|---|
| Share price | $23.44 | $5.92 |
| Market cap | $275.50M | $419.32M |
| 1-day change | -6.50% | -12.17% |
| YTD return | +3.72% | -51.44% |
| 1-year return | +72.61% | -70.53% |
| 5-year return | -76.75% | — |
| EPS (TTM) | $-39.08 | $-0.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.48M | $596.82K |
| Revenue growth (YoY) | -67.37% | +16.94% |
| Net income (latest FY) | $-242.03M | $-8.31M |
| Gross margin | — | 28.05% |
| Operating margin | -1210.58% | -883.31% |
| Net margin | -6960.77% | -1392.61% |
| 52-week high | $37.83 | $22.00 |
| 52-week low | $11.39 | $1.70 |
| Distance from 52-week high | -38.04% | -73.09% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +106.48% | — |
| Average volume | 534.47K | 289.85K |
| Shares outstanding | 11.75M | 70.83M |
| Employees | 44 | 13 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SRZN has outperformed YDES by 143.1 percentage points over the past year.
- YD Bio is more profitable, keeping -1392.6 cents of every revenue dollar as net income versus -6960.8 cents for Surrozen.
- YD Bio grew revenue faster in its latest fiscal year (+16.94% vs -67.37%).
About Surrozen
SRZN stock →Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.
Healthcare · Biotechnology · 44 employees
About YD Bio
YDES stock →YD Bio Limited, a biopharmaceutical company, focuses on regulated diagnostics, life science clinical services, and healthcare product commercialization in the United States and Taiwan. The company offers eye disease treatment products, 3D LensMate Artificial Tears, a natural tear-mimicking lubricant that moisturizes the eyes and relieves dry eye symptoms; 3D LensMate Eye Drops, an ophthalmic solution to alleviate symptoms of dry eye syndrome, including irritation, foreign body sensation, and eye fatigue; and LSC Eye Drug/Injection, an injectable ophthalmic drug is being developed for the treatment of various retinal and macular disorders, such as age-related macular degeneration, macular edema, choroidal and subretinal neovascularization, and neovascular glaucoma.
Healthcare · Biotechnology · 13 employees
SRZN vs YDES FAQ
Which is bigger, Surrozen or YD Bio?
YD Bio (YDES) is larger, with a market capitalization of $419.32M compared with $275.50M for Surrozen (SRZN).
Which stock has performed better over the past year, SRZN or YDES?
SRZN returned +72.61% over the past 12 months, compared with -70.53% for YDES (price return, excluding dividends). Past performance does not predict future results.
Are Surrozen and YD Bio in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.